| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 70.1% | 71.2% | ▲ +1.1% |
| Healthcare Services | 26.6% | 26.9% | ▲ +0.3% |
| Healthcare Equipment & Supplies | 0.6% | 0.6% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 71.2% | 70.2% | ▼ -1.0% |
| Healthcare Services | 26.9% | 26.5% | ▼ -0.4% |
| Healthcare Equipment & Supplies | 0.6% | 0.6% | ● -0.1% |
Comparing May 2026 → Jun 2026
| # | Stock | Sector | Weight (Jun 2026) |
|---|---|---|---|
| 1 | Ajanta Pharma Limited ₹37.03 Cr |
Pharmaceuticals & Biotechnology | 1.42% |
| 2 | Corona Remedies Limited ₹34.10 Cr |
Pharmaceuticals & Biotechnology | 1.31% |
| 3 | Dr. Reddy's Laboratories Limited ₹27.14 Cr |
Pharmaceuticals & Biotechnology | 1.04% |
| 4 | Jupiter Life Line Hospitals Ltd ₹7.10 Cr |
Healthcare Services | 0.27% |
| # | Stock | Sector | Last Weight (May 2026) |
|---|---|---|---|
| 1 | Laurus Labs Limited ₹74.82 Cr |
Pharmaceuticals & Biotechnology | 3.17% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹260.01 Cr |
Pharmaceuticals & Biotechnology | 9.20% | 9.96% | +0.76% |
| 2 | Rubicon Research Limited ₹44.50 Cr |
Pharmaceuticals & Biotechnology | 1.35% | 1.70% | +0.35% |
| 3 | Max Healthcare Institute Limited ₹145.53 Cr |
Healthcare Services | 5.26% | 5.57% | +0.31% |
| 4 | Cipla Limited ₹135.55 Cr |
Pharmaceuticals & Biotechnology | 4.92% | 5.19% | +0.27% |
| 5 | Shilpa Medicare Ltd ₹64.67 Cr |
Pharmaceuticals & Biotechnology | 2.28% | 2.48% | +0.20% |
| 6 | Acutaas Chemicals Ltd ₹119.54 Cr |
Pharmaceuticals & Biotechnology | 4.50% | 4.58% | +0.08% |
| 7 | Bajaj Healthcare Limited ₹19.99 Cr |
Pharmaceuticals & Biotechnology | 0.73% | 0.77% | +0.04% |
| 8 | IPCA Laboratories Limited ₹92.15 Cr |
Pharmaceuticals & Biotechnology | 3.50% | 3.53% | +0.03% |
| 9 | Gland Pharma Limited ₹31.24 Cr |
Pharmaceuticals & Biotechnology | 1.19% | 1.20% | +0.01% |
| # | Stock | Sector | May 2026 | Jun 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹186.90 Cr |
Pharmaceuticals & Biotechnology | 8.02% | 7.16% | -0.86% |
| 2 | Glenmark Pharmaceuticals Limited ₹75.14 Cr |
Pharmaceuticals & Biotechnology | 3.28% | 2.88% | -0.40% |
| 3 | Alkem Laboratories Limited ₹104.43 Cr |
Pharmaceuticals & Biotechnology | 4.36% | 4.00% | -0.36% |
| 4 | Anthem Biosciences Limited ₹99.53 Cr |
Pharmaceuticals & Biotechnology | 4.15% | 3.81% | -0.34% |
| 5 | Wockhardt Limited ₹55.00 Cr |
Pharmaceuticals & Biotechnology | 2.44% | 2.11% | -0.33% |
| 6 | Metropolis Healthcare Limited ₹58.42 Cr |
Healthcare Services | 2.54% | 2.24% | -0.30% |
| 7 | Fortis Healthcare Limited ₹82.96 Cr |
Healthcare Services | 3.41% | 3.18% | -0.23% |
| 8 | Lupin Limited ₹137.47 Cr |
Pharmaceuticals & Biotechnology | 5.45% | 5.26% | -0.19% |
| 9 | Vijaya Diagnostic Centre Limited ₹66.02 Cr |
Healthcare Services | 2.70% | 2.53% | -0.17% |
| 10 | Zydus Lifesciences Limited ₹61.07 Cr |
Pharmaceuticals & Biotechnology | 2.50% | 2.34% | -0.16% |
35 stocks — Jun 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹260.01 Cr |
Pharmaceuticals & Biotechnology |
9.96%
|
|
| 2 |
₹186.90 Cr |
Pharmaceuticals & Biotechnology |
7.16%
|
|
| 3 |
₹145.53 Cr |
Healthcare Services |
5.57%
|
|
| 4 |
₹137.47 Cr |
Pharmaceuticals & Biotechnology |
5.26%
|
|
| 5 |
₹135.55 Cr |
Pharmaceuticals & Biotechnology |
5.19%
|
|
| 6 |
₹131.87 Cr |
Healthcare Services |
5.05%
|
|
| 7 |
₹119.54 Cr |
Pharmaceuticals & Biotechnology |
4.58%
|
|
| 8 |
₹104.43 Cr |
Pharmaceuticals & Biotechnology |
4.00%
|
|
| 9 |
₹99.53 Cr |
Pharmaceuticals & Biotechnology |
3.81%
|
|
| 10 |
₹92.15 Cr |
Pharmaceuticals & Biotechnology |
3.53%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.